Comorbidities in patients with chronic obstructive lung disease and COVID-19 in Almaty (Kazakhstan Republic)

Q4 Medicine

Pulmonologiya Pub Date : 2022-12-11 DOI:10.18093/0869-0189-2022-32-6-923-926

G. Esetova, L. R. Idrisova, S. S. Salimova, B. Konysbay, D. Batyrbay, T. Muminov

{"title":"Comorbidities in patients with chronic obstructive lung disease and COVID-19 in Almaty (Kazakhstan Republic)","authors":"G. Esetova, L. R. Idrisova, S. S. Salimova, B. Konysbay, D. Batyrbay, T. Muminov","doi":"10.18093/0869-0189-2022-32-6-923-926","DOIUrl":null,"url":null,"abstract":"SARS-CoV-2 (Severe Acute Respiratory Syndrome-related CoronaVirus 2) infection is characterized by multi-comorbidity, which increases the severity of the disease. The aim of the study was to identify the relationship between the length of stay in the hospital and the comorbidity and the severity of lung damage. Methods. 72 patients with COVID-19 (COronaVIrus Disease 2019) infection were studied, including 33 women and 39 men who were treated in the city hospitals. The average age was 67.4 ± 12.02 years. The SARS-CoV-2 RNA virus was identified by PCR in 46 (63.8%) patients. Results. The most common comorbidities in chronic obstructive pulmonary disease (COPD) patients with COVID-19 included arterial hypertension (in 32%), coronary artery disease (17%), and type 2 diabetes (10%). The majority of patients (48.7%) had the CT II stage. The total proportion of patients with an advanced damage (corresponding to CT III - IV) was 36.2%. Mean hospitalization length was 13.8 ± 7.9 days. Conclusion. COPD patients with COVID-19 infection included a significant percentage of patients with arterial hypertension, which required additional treatment.","PeriodicalId":37383,"journal":{"name":"Pulmonologiya","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18093/0869-0189-2022-32-6-923-926","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

SARS-CoV-2 (Severe Acute Respiratory Syndrome-related CoronaVirus 2) infection is characterized by multi-comorbidity, which increases the severity of the disease. The aim of the study was to identify the relationship between the length of stay in the hospital and the comorbidity and the severity of lung damage. Methods. 72 patients with COVID-19 (COronaVIrus Disease 2019) infection were studied, including 33 women and 39 men who were treated in the city hospitals. The average age was 67.4 ± 12.02 years. The SARS-CoV-2 RNA virus was identified by PCR in 46 (63.8%) patients. Results. The most common comorbidities in chronic obstructive pulmonary disease (COPD) patients with COVID-19 included arterial hypertension (in 32%), coronary artery disease (17%), and type 2 diabetes (10%). The majority of patients (48.7%) had the CT II stage. The total proportion of patients with an advanced damage (corresponding to CT III - IV) was 36.2%. Mean hospitalization length was 13.8 ± 7.9 days. Conclusion. COPD patients with COVID-19 infection included a significant percentage of patients with arterial hypertension, which required additional treatment.

查看原文本刊更多论文

阿拉木图(哈萨克斯坦共和国)慢性阻塞性肺病患者与COVID-19的合并症

SARS-CoV-2(严重急性呼吸综合征相关冠状病毒2)感染具有多重合并症的特点，这增加了疾病的严重程度。该研究的目的是确定住院时间与合并症和肺损伤严重程度之间的关系。方法:对72例2019冠状病毒病(COVID-19)感染患者进行研究，其中女性33例，男性39例。平均年龄67.4±12.02岁。46例(63.8%)患者PCR检测出SARS-CoV-2 RNA病毒。结果。慢性阻塞性肺疾病(COPD)合并COVID-19患者最常见的合并症包括动脉高血压(32%)、冠状动脉疾病(17%)和2型糖尿病(10%)。大多数患者(48.7%)为CT II期。晚期损害(对应于CT III - IV)患者的总比例为36.2%。平均住院时间13.8±7.9天。结论。感染COVID-19的COPD患者包括相当比例的动脉高血压患者，这需要额外的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pulmonologiya Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The aim of this journal is to state a scientific position of the Russian Respiratory Society (RRS) on diagnosis and treatment of respiratory diseases based on recent evidence-based clinical trial publications and international consensuses. The most important tasks of the journal are: -improvement proficiency qualifications of respiratory specialists; -education in pulmonology; -prompt publication of original studies on diagnosis and treatment of respiratory diseases; -sharing clinical experience and information about pulmonology service organization in different regions of Russia; -information on current protocols, standards and recommendations of international respiratory societies; -discussion and consequent publication Russian consensus documents and announcement of RRS activities; -publication and comments of regulatory documents of Russian Ministry of Health; -historical review of Russian pulmonology development. The scientific concept of the journal includes publication of current evidence-based studies on respiratory medicine and their discussion with the participation of Russian and foreign experts and development of national consensus documents on respiratory medicine. Russian and foreign respiratory specialists including pneumologists, TB specialists, thoracic surgeons, allergists, clinical immunologists, pediatricians, oncologists, physiologists, and therapeutists are invited to publish article in the journal.